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Abstract 19 
Brugada Syndrome (BS) is an inherited channelopathy associated with a high incidence of 20 
sudden cardiac death. The article presents the discovery of new genetic variants at SCN5A 21 
gene which might be associated with the development of concealed form of Brugada 22 
Syndrome. The study involved a group of 59 patients (37 men) with suspected concealed 23 
form of Brugada Syndrome. Pharmacological provocation with intravenous ajmaline 24 
administration was performed. Six patients with positive test result were subjected to 25 
molecular analysis of SCN5A gene with MSSCP method. Additionally, MSSCP genotyping 26 
was performed for samples obtained from the family members with Brugada Syndrome, 27 
despite they had negative ajmaline challenge test results.Genetic examinations of the SCN5A 28 
gene at 6 positive patients showed 6 known polymorphisms, 8 new single nucleotide point 29 
(SNP) variants located at exons and 12 new single nucleotide point variants at introns. Among 30 
detected in exons SNP, two of them were synonymous SNPs (no change in the coded amino 31 
acids), whereas 3 represented non-synonymous SNPs and affected the protein sequences.  32 
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INTRODUCTION 2 
About 5-10% of sudden cardiac death (SCD) cases are caused mainly by electrical heart 3 
diseases [1]. In the recent years, a special attention has been paid to one of them, the Brugada 4 
Syndrome (BS). The diagnosis of BS is based on ECG criteria as well as on the clinical 5 
picture. Typical BS ECG changes occur as a result of ion function disorders in the heart, 6 
which are caused by genetic mutations and lead to improper course mainly of repolarization 7 
processes in cardiomyocytes. Electrocardiographic features of the syndrome are dynamic and 8 
ECG curve is periodically normal – typical BS characteristics disappear, which makes it 9 
difficult to diagnose BS. Concealed form of BS causes underestimation of this disease 10 
occurrence frequency and a great number of people remain undiagnosed. Specific 11 
pharmacological provocation tests with class I medicine are critical in reveling concealed 12 
ECG features of BS. 13 
Genetic background of the BS  14 
The first gene to be linked to BS is the SCN5A, the gene that encodes the α-subunit of the 15 
cardiac sodium channel gene [2].  Almost 400 mutations at the SCN5A genehave been 16 
indentified at the syndrome patients since 2001 [3, 4]. Numerous detected mutations have 17 
been studied at the functional level [5]. The mutations at the SCN5A geneoccur in 18 
approximately 18% to 30% of BrugadaSyndrome cases. A higher incidence of SCN5A 19 
mutations has been reported in familial rather than in sporadic cases [6].  20 
Another gene loci on chromosome 3, which is close to but distinct from SCN5A, have 21 
recently been linked to the syndrome (3p22-p24) [6] and GPD-1L [8]. Those mutations 22 
resulted in the loss of function of the cardiac sodium channel. Another genes associated with 23 
BS were reported in the last years and shown to encode the α1 and β subunits of the L-type 24 
cardiac calcium channel [9].  25 
The SCN5A gene remains the main gene linked to BS. Of note, negative SCN5A results 26 
generally do not rule out causal gene mutations. Current, knowledge of a specific mutation 27 
may not provide guidance in formulating a diagnosis or determining a prognosis. Mutation 28 
screening of the SCN5A gene in patients with BS may only support a clinical overt or 29 
suspicious diagnosis. 30 
In recent years the genotyping of SCN5A gene were more correlated to the prognostic 31 
value than to the diagnosis of the BS itself. Some of the SCN5A mutations were related to a 32 
worse clinical course[10], and other with the better [11] prognosis of the BS patients.  33 
MATERIALS AND METHODS 1 
Patient populations 2 
The study involved a group of 59 Polish patients (37 men) with suspected concealed BS based 3 
on specific ECG and/or clinical criteria: 4 
- complete and incomplete right bundle branch block (RBBB) in ECG,  5 
- suspected but non-diagnostic ECG (type 2 and 3),  6 
- history of sudden cardiac arrest (SCA),  7 
- unexplained syncopes, 8 
- sudden cardiac death (SCD) amongst family members under 45,  9 
-  family history of BS. 10 
The protocol of the study has been approved by the Commission for Bioethics. Written 11 
informed consent was obtained from all of the patients. 12 
The ajmaline challenge test 13 
All patients were performed withpharmacological provocation with intravenous ajmaline 14 
administration dosed 1mg/kg body weight for 5 min, in safe conditions during 12-lead 24-15 
hour Holter ECG monitoring. 16 
In patients with positive test result, molecular tests of the SCN5A gene were performed.  17 
Molecular tests were performed in the family members of patients with BS, even if the 18 
pharmacological provocation test was negative in these individuals.  19 
Occurrence of type 1 electrocardiographic patterns (cove-shaped ST elevation in right 20 
precordial leadswith J wave or ST elevation of ≥2mm (mV) at its peak followed by a negative 21 
T wave withlittle or no isoelectric interval in more than one right precordial leads V1-V3) or 22 
conversion of types 2 or 3 to the diagnostic type 1 pattern after ajmaline administration was 23 
considered as a positive test result [3]. Occurrence of type 2 or 3 ST segment elevation was 24 
considered as negative test result.   25 
DNA analysis 26 
The genetic analysis was conducted in collaboration with Kucharczyk TE/BioVectis 27 
Company (Warsaw, Poland). Genomic DNA were analysed in 7 patients with positive result 28 
of ajmaline challenge test (one patient with positive result of ajmaline challenge test did not 29 
agree to be genotyped), and in 1 family member of patients with negative result of ajmaline 30 
challenge test. Genomic DNA were extracted from peripheral blood leucocytes (100 μ l of 31 
frozen blood was used). Isolation was performed according to the manufacturer’s protocol 32 
(A&A Biotechnology, Poland). Regions most likely to contain genetic mutations at 28 exons 33 
of the SCN5A gene were covered by 41 PCR amplicons, covering 28 exons and partial intron 34 
sequences, as previously described [12]. Several pairs of primers were synthesized to PCR 1 
amplify exons 12, 17 and 28 due to their large sizes, named as a 12a, 12b, 17a etc. PCR 2 
primers were designed to cover the full coding sequence (exons), as well as, partial fragments 3 
of flanking non-coding fragments (introns). The PCR products were separated on agarose gel 4 
to examine their specificity and to normalise the DNA concentration. Next, 328 PCR products 5 
were screened by multitemperature single strand conformation polymorphism (MSSCP) [13] 6 
method for the presence of a single point mutation or a polymorphism. The MSSCP 7 
conditions were individually optimized for each PCR product. MSSCP was performed on 7 to 8 
10%T polyacrylamide gels, 3.3%C at 0.75× TBE buffer. For some regions glycerol was 9 
added to polyacrylamide gel up to 5% w/v concentration. MSSCP analysis was performed 10 
using DNAPointer System in 0.5× TBE buffer. Temperature profile of electrophoresis was 11 
35–15–5°C. Electrophoresis was performed with 40 W of electrical power. Before applying 12 
samples onto the gel, 10 min of preelectrophoresis (40 W at 35°C) was performed. At the 13 
beginning samples were maintain for 10 min at 100 V for concentration. Subsequently, 14 
MSSCP separation was made. The PCR products that have altered MSSCP mobility were 15 
followed by Sanger method. 20 ng DNA of PCR products were used as a matrix for 16 
sequencing reaction. Both strands were sequenced at PCR products that revealed a genetic 17 
alternation. Genetic alterations were identified using the BLAST (Basic Local Alignment 18 
Search Tool) program and its BLASTN version as well as UCSC (University of California 19 
Santa Cruz) Genome Bioinformatics and NCBI (National Center for Biotechnology 20 
Information) databases of single nucleotide polymorphisms (SNPs).  21 
Functional analysis of SCN5A variants 22 
An in silicoanalysis was performed to evaluate the putative functional impact of the three 23 
identified variations (S321Y, S519F and K974D). We used the Polymorphism phenotyping-2 24 
(PolyPhen-2) server [14], which integrates sequence-based and structure-based features to 25 
predict amino acid substitution effects using a naïve Bayes classifier. An amino acid change 26 
was classified as “probably damaging” if its probability score was greater than 0.85 or as 27 
“possibly damaging” if the score was between 0.85 and 0.55. To assess the influence of 28 
putative unstructured regions we used DISOPRED3 [15] software along with DOMPRED 29 
[16] to predict possible domain boundaries and disordered binding regions. Finally, we used 30 
Phyre [17] for structural feature predictions, mainly transmembrane regions and secondary 31 
structure using three different algorithms.  32 
 33 
RESULTS 1 
Patient demographics 2 
Study inclusion criteria were met by 59 patients (22 women and 37 men) (Table 1). 3 
Average age of the group was 31.6 ± 12.2 years, from 16 to 62 years.  Average age for 4 
women was 29.68 ± 10.9 years while for men 32.8 ± 12.9 years. The majority of patients 5 
(72.8%) was under 40.  6 
Echocardiography in all the included patients revealed no significant organic heart 7 
disease.  8 
Clinical characteristic of the group with positive result of pharmacological provocation 9 
test 10 
Pharmacological provocation test was carried out on the whole study group. No 11 
significant undesirable effects were observed. None of the patients met the criteria of 12 
discontinuation prior the scheduled conclusion of the study.  13 
Positive test result - type 1 ST segment elevation (Fig.1a) - which was considered as 14 
diagnostic for BS was obtained in 7 individuals (11.86%). The other 52 patients (88.14%) had 15 
negative provocation test result (Fig. 1b).  16 
The group of 7 patients with type 1 ST segment elevation diagnostic for BS following 17 
ajmaline administration consisted of 6 men (85.7%) and 1 woman (14.3%). Average age of 18 
this group was 36.5 ±15.2, from 16 to 52 years. The group of patients with negative test result 19 
included 31 men (59.6%) and 21 women (40.4%). Average age of this group was 30.9 ±11.7, 20 
from 18 to 62 years. No statistically significant corelation between gender, age or body mass 21 
and ajmaline test was observed.  22 
 As regards the group of 7 individuals with positive  provocation test result, 2 patients 23 
had history of SCA (men), among which in 1 person the diagnosed SCA mechanism was 24 
ventricular fibrillation. The SCA mechanism in the second individual remains unknown. Both 25 
patients were implanted a cardioverter – defibrillator. Within the group of the other 5 patients, 26 
initially considered as asymptomatic, 16 month following the provocation test syncopes 27 
occurred in 1 person (woman), what was an indication for implanting a cardioverter-28 
defibrillator. The other 4 individuals have remained asymptomatic during the observation 29 
period lasting from 39 to 60 months.  30 
Results of MSSCP analysis and DNA sequencing of the SCN5A sodium gene   31 
Genetic examinations of SCN5A gene showed 6 known polymorphisms: rs6599230 (A›G, 32 
A29A), rs41312393 (A›G, intron), rs1805126 (T›C, A1818G), rs7429945 (A›G, exon, non-33 
translated region), rs41315485 (T›C, exon, non-translated region) and rs7430407 (A›G, 34 
E1061E). Three of them were noted at regions of coding proteins, two at non-coding regions 1 
and one at intron. Numerous new genetic variants were detected at: non-translated regions (8 2 
SNP), at introns (12 SNP), in the protein coding regions (5 SNP) – 2 DNA sequence variants 3 
caused no change in the coded amino acid, whereas 3 altered the coded amino acid.  4 
An example of MSSCP analysis of 2 amplicones, no 2 and 7, of the SCN5A gene for 8 5 
particular patients is presented in (Figure 2). On the other hand, Figure 2 shows an example of 6 
patients derived-ampliconessequence analysis, which were compared with reference 7 
sequences (Figure 3). All detected polymorphisms were further analyzed in context of their 8 
localization and its impact on aa SCN5A protein sequence.  9 
Known polymorphisms 10 
The rs6599230 polymorphism at exon 2 of the SCN5A gene was found in 2 patients 11 
related with each other. It involved an alteration of nucleotides in 38614716 position (A›G) of 12 
reference sequence, however, detected variant did not alter the aa in protein sequence (A29A), 13 
thus had no impact on protein functionThe patients with this variant were a man (father) and a 14 
woman (daughter), both asymptomatic. The pharmacological provocation test was positive in 15 
the man and negative in the woman. 16 
 On the other hand,in exon 17b of the SCN5A gene, a known rs7430407 polymorphism 17 
was identified in 1 person. It involved a nucleotide alteration in 38562471 position (A›G) of 18 
reference sequence. The patient with this variant was a man with asymptomatic BS diagnosed 19 
based on pharmacological provocation. This genetic alteration caused no amino acid changes 20 
in protein sequence (E1061E).  21 
Genotyping of exon 24 of the SCN5A gene revealed a known rs41312393 polymorphism 22 
in 3 individuals. It involved an alteration in nucleotides in 38538672 position (A›G) of 23 
reference sequence and was located at intron. The 3 persons were asymptomatic – 2 men with 24 
positive pharmacological provocation test and a woman related to one of the men (daughter) 25 
with negative result. 26 
At exon 28c of the SCN5A gene a known 1805126 polymorphism was identified in 4 27 
patients. This genetic change involved a nucleotide alteration in 38532410 position (T›C) of 28 
reference sequence and caused no change in the amino acid sequence in the coded protein 29 
(D1818D). Clinically, they were 2 asymptomatic individuals related to each other (father and 30 
son); one had negative result of pharmacological provocation (father) whereas the second 31 
patient had type 1 change in ST segment typical of BS. The other 2 patients were not related; 32 
one was a man with symptomatic BS and with history of SCA while the second was a man 33 
with asymptomatic BS.  34 
Further, analysis of exon 28f of the SCN5A gene revealed the presence of  known 1 
rs7429945 polymorphism, that was detected in 7 patients. It involved a nucleotide alteration 2 
in 38531693 position (A›G) of reference sequence. This genetic change occurred in the non-3 
translation part of the exon in 6365 mRNA position. The described genetic change was 4 
present in almost every patient. Its presence was not observed only in a man with 5 
symptomatic BS and history of SCA.  6 
Another known polymorphism is rs41315485 identified in 6 patients at exon 28k of the 7 
SCN5A gene. It involved an alteration in nucleotides in 38530279 position (T›C) of reference 8 
sequence, in 7779 mRNA position and was located in the non-translation region. The 9 
polymorphism was not observed only in 2 individuals from the analyzed group. They were 10 
men (brothers) – one with symptomatic and the other with asymptomatic BS.  11 
New genetic variants in non-translation regionsat exons 12 
At exon 1 of the SCN5A gene a new polymorphism that involved an alteration in 13 
nucleotides in 38631119 position (G›A) of reference sequence in 49 mRNA position was 14 
observed. The change was connected with the region transcribed on mRNA but is not 15 
translated as a protein. The person with this genetic variant was a man with diagnosed 16 
symptomatic BS (with history of SCA). The polymorphism was not observed in other 17 
patients.  18 
Another new DNA sequence changes was observed in 2 patients who were related with 19 
each other. It was connected with the change in nucleotides in 38614815 position (G›C) of 20 
reference sequence found at exon 2. The genetic variant was present in 182 mRNA position 21 
and was related to a non-translation mRNA part. The patients with this polymorphism (a 22 
woman and a man) were asymptomatic; pharmacological provocation test was positive in the 23 
man and negative in the woman.  24 
A new DNA sequence changewas also observed at exon 28g of the SCN5A gene in 5 25 
patients. It involved an alteration in nucleotides in 38531355 position (G›A) of reference 26 
sequence in 6703 mRNA position. The genetic alteration was present in a non-translation part 27 
of the exon. The 5 individuals included 2 men with symptomatic BS and history of SCA. 28 
Moreover, the group included the brother and the father of the patient with history of SCA, 29 
one with negative and the second with a positive result of pharmacological provocation test. 30 
The last person with this polymorphism was a man with asymptomatic BS.  31 
Genotyping of exon 28i of the SCN5A gene revealed  4 new polymorphismslocalized in a 32 
non-translation part of the exon. These changes were found in all the examined persons, 33 
among which 4 patients had all the 4 genetic variants, 3 patients had two new sequence 34 
changes: in 38530974 (C›T) and 38531102 (C›T) position of reference sequence, while 1 
polymorphism in 38530974 position (C›T) was observed in all the patients.  2 
Further, analysis of exon 28l of the SCN5A gene showed a new sequence variant in 3 
38529996 position (C›G) of reference sequence in 8062 mRNA position. The change was 4 
found only in 1 person. Clinically, the person with this polymorphism was a man with 5 
asymptomatic BS.  6 
New polymorphisms in protein coding regions that cause no alteration in the coded amino 7 
acid  8 
As regards the group of 8 examined patients, 2 unknown genetic variants were observed 9 
in one patient at exon 28c of the SCN5A gene in protein coding regions; they caused no 10 
change in the coded amino acid thus we should consider them as a polymorphic change. The 11 
two novel polymorphic variants were detected in positions: 38532614 (C›T, F1750F) and 12 
38532617 (C›T, L1749L). In both cases the changed nucleotide is in the 3 codon position, 13 
which may influence the fact that it causes no alteration in the amino acid sequence. These 14 
genetic variants were observed in a patient with diagnosed BS and history of SCA who 15 
required implantation of cardioverter-defibrillator.  16 
New sequence changes in the protein coding regions that alter the coded amino acid 17 
During genetic analysis of the SCN5A gene presence of 3 unknown genetic variants that 18 
altered the coded amino acid were found in 5 patients.  19 
The first variantcontained change in nucleotides in 38589682 position (C›A) of reference 20 
sequence and was observed in 1 patient with negative result of pharmacological provocation. 21 
This genetic change was observed in exon 8 of the SCN5A gene. It altered serine amino acids 22 
into tyrosine in 321 position of the coded protein (S321Y). This variant was found in none of 23 
the other patients.  24 
Another genetic variant detected in one patient involved a change in nucleotides in 25 
38585541 position (C›T) of reference sequence which altered serine amino acids into 26 
phenylalanine in 519 protein position (S519F). New variant was found at exon 12 of the 27 
analyzed gene. The change was observed in a patient with asymptomatic BS and its presence 28 
was confirmed neither in 2 family members of the patient nor in the other examined patients.  29 
 The last new sequence variant, which according to the UCSC GenomiBioinformatic 30 
database is found in the protein coding region, was observed in 4 patients. The polymorphism 31 
was observed at exon 17 of the SCN5A gene and involved a change in amino acids in 32 
38562732 position (G›T) of reference sequence. This genetic change altered lysine amino 33 
acids into aspartic acid in 974 position of the coded protein (K974D). BS was diagnosed in 2 34 
of the persons while the other 2 individuals were family members of patients with negative 1 
results of pharmacological provocation. Schematic representation of detected changes is 2 
illustrated on Figure 4. To evaluate the possible influence of new missense mutations on 3 
channel function, bioinformatics analysis has been conducted.  4 
In silico functional analysis of SCN5A variants 5 
The three variants identified are located at the cytoplasmic region of the SCN5A-encoded 6 
protein (Figure 5A). Confirmed disease associated genetic variants can be found in close 7 
proximity to each one of the new variants, as well as sites of aminoacid modifications (e.g. 8 
arginine methylation site at 513 and 526 or a glicosylation site at 318). This would hint that 9 
the observed variants are located in important regions for protein function. To further explore 10 
their possible functional impact we employed a well known bioinformatics algorythm Poly-11 
Phen2. The tool indicated a high possibility of damage caused by mutating K974D with 12 
prediction score close to 1 (highest possible) (Figure 5B). For the two other mutations 13 
possible damage was also reported, but with lesser probability. We sought to confirm these 14 
predictions with more structural insights. We used three different software tools to establish 15 
whether these variations would occur in unstructured and putative domain regions. Indeed 16 
S519F is located in a large domain of unknown function (DUF3451, PFAM: PF11933), which 17 
is also predicted as an unstructured/disorderd region by all three bioinformatics methods 18 
(Figure 5C). This would suggest a possible protein-binding interaction in this region which 19 
could be hampered by this variant (especially since serine contains a hydroxylic polar group 20 
and phenyloalanine is hydrophobic and aromatic). On the other hand S321Y is also located in 21 
Transmembrane ion channel family domain (Ion_trans, PF) which is predicted to be 22 
structured. The same goes with K974D, located just at the beginning of the Sodium ion 23 
transport-associated domain (Na_trans_assoc, PF:). Again, this is a structured region but very 24 
close to predicted unstructured binding region (945-956).  25 
New point mutations found at introns 26 
In the regions of the SCN5A gene, which according to the UCSC Genomic Bioinformatic 27 
database are at introns, 12 new point mutations were found.  28 
MSSCP analysis of exon 4 of the SCN5A gene detected 4 new mutations within the 29 
intron. The first was a mutation in 38603806 position of reference sequence and involved a 30 
type A insertion. The second mutation was an alteration in nucleotides in 38603801 position 31 
(T›A) of reference sequence. The two said genetic changes were confirmed in 5 patients, 32 
among which 3 were asymptomatic and 2 were symptomatic (1 with history of SCA and 1 33 
with syncopes). Another genetic change detected at this exon in 2 other individuals was a 34 
change in nucleotides in 38604076 position (G›T) of reference sequence. The first patient had 1 
positive provocation result and history of SCA whereas the second patient was asymptomatic 2 
and also had positive provocation result. The last sequence change at this exon was found 3 
only in one patient in 38604075 position (G›T) of reference sequence. The patient was 4 
asymptomatic with negative result of ajmaline test.   5 
MSSCP analysis showed presence of 2 new genetic variants at exon 6 of the SCN5A gene 6 
within the intron in 7 patients out of 8. The first involved a change in nucleotides in 38595390 7 
position (C›G) of reference sequence. The second mutation was a change in 38595384 8 
position (C›G) of reference sequence. These DNA variants were observed in all the examined 9 
patients apart from one individual who was asymptomatic and had negative result of 10 
pharmacological provocation test. At exon 7 of the SCN5A gene a DNA sequence variant 11 
within the intron (pos. 38591480, C›G) was identified in 4 patients out of 6 with positive 12 
ajmaline provocation test. Moreover, 3 patients from this group had symptomatic BS and had 13 
an implanted cardioverter-defibrillator either due to history of SCA or unexplained syncopes. 14 
Concurrently, this polymoprhism was confirmed in neither of the patients with negative result 15 
of provocation test. The results of MSSCP genotyping of 41 amplicones represented SCN5A 16 
gene are summarized in Table 2. Additionally, Table 3 contains the list of intronic alterations 17 
and exchanges in non-coding regions along with short stretches of sequences alignments 18 
(WT/MT).  19 
 20 
DISCUSSION 21 
The major gene related with BS is the SCN5A gene. Despite the great development in 22 
molecular studies, it is estimated that mutations in the SCN5A gene cause only about 18-30% 23 
of BS cases [18]. These mutations are more common in familial cases of the disease rather 24 
than sporadic ones [19]. Negative results of genetic studies do not exclude causal gene 25 
mutations. Neither diagnosis nor prognosis of BS can be based on genetic test results. In the 26 
presented work a molecular analysis of the whole the SCN5A gene was carried out with 27 
respect to patients with positive provocation test (apart from 1 person who failed to give their 28 
informed consent) as well as their family members (1st degree of kinship) who gave their 29 
informed consent. Due to both low predicted BS incidence in the Polish population (lack of 30 
accurate data) and a considerably low percentage of the known genetic changes being the 31 
underlying cause of the disease (18-30% as above), the work was limited only to analyzing 32 
the occurrence of the known mutations. The molecular study of the 28 exons and short 33 
exon/intron fragments of SCN5 gene was carried out including also the alterations in the 34 
sequence of the few non-coding regions of the gene (introns). In this study, the new genetic 1 
variants were found both at exons and introns. It is a commonly accepted fact that the effects 2 
of DNA sequence change depend on their location in the gene. However, all too often, it is 3 
assumed that only genetic alterations in the coding sequences, i.e. at exons, have an impact on 4 
the clinical course of the disease. Recent studies and findings have shown that intronic 5 
mutations may play a major role in the splicing process, alter its course, lead to coding 6 
sequence abnormalities and consequently influence the structure and function of the encoded 7 
proteins. Numerous data reported in scientific papers show that both intronic and exonic 8 
alterations may result in an aberrant splicing process, leading to the formation of abnormal 9 
proteins, what in turn affects the severity of the disease symptoms. These 10 
mutations/polymorphisms at introns leading to the disturbances of the splicing process are 11 
described in the disorders of cardiovascular system [20].   12 
In the course of DNA analysis of the SCN5A sodium gene the following 6 known 13 
polymorphisms were identified: rs6599230, rs41312393, rs1805126, rs7429945, rs41315485 14 
and rs7430407. In this group 3 polymorphisms were observed in the protein coding regions, 2 15 
– in the non-translation regions and one at the intron. Neither of them had been associated 16 
with BS before. Also, 8 new genetic variants were found at exons in the non-translation 17 
regions, 12 at introns, 2 in the protein coding regions that cause no change in the coded amino 18 
acid and. None of 3 point mutations (S321Y, S519F and K974D) in the protein coding 19 
regions that alter the coded amino acid has been associated previously with BS [5]. According 20 
to Zimmer et al., as well as bioinformaticanalysiswe are able to localize their positions in 21 
protein sequence.  S321Y is localized in the intracellular loop III, S519F in the intracellular 22 
loop IV, whereas K974D is localized in the C-terminal intracellular fragment of SCN5a 23 
protein. According to the bioinformatic results, K974D aa alteration is recognized as a highly 24 
damaging for protein function (prediction score amounted about 1, the highest possible). Two 25 
other aa changes were also reported as possible damage, however their probability score 26 
amounted from 0.85 to 0.55.  27 
As mentioned previously, also intronic changes could affect protein function. We 28 
performed some basic bioinformatic analysis of detected changes, however we obtained 29 
contradictory data. Due to the large number of detected polymorphisms in introns, we decided 30 
to perform more detailed analysis, including in vitro studies.  31 
The majority of detected polymorphisms and genetic changes found in the study had 32 
never been reported as mutations leading to development of BS. The lack of data in the 33 
literature and the lack of a population control for this part of the SCN5A gene made it 34 
impossible to state clearly whether the BS syndrome were significantly associated with 1 
mentioned changes. It is also noteworthy, that several genes are associated with BS syndrome, 2 
thus further genetic study are needed. However, at least new polymorphisms/mutations that 3 
were found in our patients of a specific phenotype are worth considering.  4 
Special attention ought to be paid to genetic changes present only in symptomatic 5 
patients, e.g. with history of SCA. These genetic changes include:  6 
 a new polymorphism which involves an alteration in nucleotides in 38631119 position 7 
(G›A) of reference sequence in 49 mRNA position and developed in a man with 8 
history of SCA and BS diagnosed on the basis of provocation test result; it was found 9 
in none of the other patients;  10 
 a new genetic variant at exon 28 which involves an alteration in nucleotides in 11 
38531355 position (G›A) of reference sequence in 6703 mRNA position and 12 
developed in 5 patients including 2 men with positive provocation test results and 13 
history of SCA as in other individuals (i.e., the brother and the father on one of these 14 
men); 15 
 two new genetic variants at exon 28c in the protein-coding regions with no alteration 16 
in the coded amino acid (C›T, I1749I; C›T, F1750F) both developed in a man with 17 
history of SCA and positive provocation test result;  18 
 a new polymorphism at exon 7 which involves an alteration in nucleotides in 19 
38591480 position (C›G) of reference sequence and developed in 4 patients out of 6 20 
individuals with positive ajmaline provocation test; 3 of these patients had 21 
symptomatic BS following implantation of cardioverter-defibrillator either due to 22 
history of SCA or unexplained syncopes; concurrently the mutation was confirmed in 23 
none of the patients with negative provocation test result;  24 
Considering new data on the role of genetic changes not only in BS diagnostics but also 25 
in prognosis for diagnosed patients [21, 22], further studies aimed at determining the role of 26 
the identified genetic disorders seem to be extremely interesting.  27 
 28 
CONCLUSIONS 29 
New genetic variants/polymorphism in the SCN5A gene are present in patients with 30 
concealed form of Brugada Syndrome, yet their role in pathogenesis requires further studies.  31 
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Inclusion criteria Number of included patients 
RBBB in ECG (complete and incomplete) 35 patients (59.32%) 
- RBBB complete – 8 patients (13.6%) 
- RBBB incomplete – 27 patients (45.76%) 
History of SCA , 7 patients (11.8%) 
Unexplainedsyncopes, 31 patients (52.5%) 
SCD amongst family members under 45, 
 
5 patients (8.5%) 
Family history of Brugada syndrome, 4 patients (6.8%) 
Suspected but non-diagnostic ECG  
(type 2 and 3). 
16 patients (27.11%) 
- type 2  – 4 patients (6.78%) 
- type 3 – 12 patients (20.33%) 
Tab. 1. Distribution of the examined population depending on inclusion criteria.  2 
 3 
 Major clinical data 
Genetic alterations in DNA sequences of SCN5amplicones 





Father of the patient with 
diagnosed BS 
amplicone 4: Pos . 38603806, insertion A, intron 
                      Pos . 38603801 homozygote A, intron  
amplicone 8: Pos . 38589643 insertion A, intron  
                      Pos . 38589682 C›A, amino acid pos . 321, S>Y 
amplicone 17a: Pos . 38562732 G›T, amino acid pos. 974, K>D 
amplicone 28c: Pos . 385924060 T›C, exon, amino acid pos . 1818 D>D, 
rs1805126  
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs 7429945 
amplicone 28g : Pos. 38531355 heterozygote G›A, mRNA position 6703, 
near 3’UTR, non-translated region 
amplicone 28i : Pos . 38530974 C›T, exon, mRNA posi tion 7084, near 3’UTR, 
non-tranlated region 
                      Pos . 38531102 C›T, exon, mRNA position 6956, near 3’UTR, 
non-translated region 
amplicone 28k: Pos. 38530279 T›C, exon, mRNA pos . 7779, 3’UTR, non -
translated region, polimorphism rs41315485 
Patient 2 
History of sudden cardiac 
arrest 
Posi tive pharmacological 
amplicone 4: Pos . 38603806, insertion A, intron 
                      Pos . 38603801 homozygote T›A, intron  
amplicone 6: Pos. 38595390 G›C, intron 
provocation test 
Diagnosed BS 
                      Pos. 38595384 homozygote G›C, intron 
amplicone 7: Pos . 38591480 C›G, intron 
amplicone 28g: Pos. 38531355 G›A, exon, mRNA position 6703, near 
3’UTR, non-translated region 
amplicone 28i : Pos . 38530974 G›A, exon, mRNA position 7084, near 3’UTR, 
non-translated region 
Patient 3 
History of sudden cardiac 
arrest 
Posi tive pharmacological 
provocation test 
Diagnosed BS 
amplicone 1: Pos . 38631119 G›A, mRNA pos  49, non-translated region  
amplicone 4: Pos . 38604076 G›T, intron  
amplicone 6: Pos. 38595390 homozygote C›G, intron 
                      Pos. 38595384 homozygote C›G, intron  
amplicone 7: Pos . 38591480 C›G, intron 
amplicone 17a: Pos . 38562732 G›T, amino acid pos. 974, K>D 
amplicone 28c: Pos. 38532617 C›T, exon, amino acid pos. 1749, I>I 
                          Pos .  38532614 C›T, exon, amino acid position 1750, F>F 
                          Pos . 38592406T›C, exon, amino acid pos . 1818, D>D, 
rs1805126 
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs 7429945 
amplicone 28g : Pos. 38531355 heterozygote G/A, mRNA posi tion 6703, 
near 3’UTR, non-translated region 
amplicone 28i : Pos . 38530974 C›T, exon, mRNA posi tion 7084, near 3’UTR, 
non-translated region 
                          Pos . 38531102 C›T, exon, mRNA position 6956, near 3’UTR, 
non-translated region 
amplicone 28k: Pos. 38530279 T›C, exon, mRNA pos . 7779, 3’UTR, non -
translated region, polimorphism rs41315485 
Patient 4 
Asymptomatic 
Posi tive pharmacological 
provocation test 
Brother of the patient with 
diagnosed BS 
amplicone 4: Pos . 38604076 G›T, intron  
amplicone 6: Pos. 38595390 homozygote C›G, intron 
                      Pos. 38595384 homozygote C›G, intron  
amplicone 12a: Pos . 38585541 C›T exon, amino acid pos . 519, S>F 
                       Pos . 38585647 homozygote A›T, intron 
amplicone 22:Pos  38544050, heterozygote C/T, intron 
amplicone 24: Pos  38547178 heterozygote A/G, intron, polymorphism 
rs41312393 
amplicone 28c: Pos . 38592406 T›C, exon, amino acid pos . 1818, D>D, 
rs1805126 
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs 7429945 
amplicone 28g: Pos . 38531355 G›A, exon, mRNA position 6703, near 
3’UTR, non-translated region 
amplicone 28i : Pos . 38530974 C›T, exon, mRNA posi tion 7084, near 3’UTR, 
non-translated region 




Posi tive pharmacological 
provocation test 
Father of the patient with 
diagnosed BS 
amplicone 2: Pos . 38614716 A›G, exon, amino acid pos . 29, A>A, 
polymorphism rs6599230 
                      Pos . 38614815, G›C, exon, mRNA pos.182, non -translated 
region  
amplicone 4: Pos . 38604075 homozygote G›T, intron  
amplicone 6: Pos. 38595390 homozygote C›G, intron 
                      Pos. 38595384 homozygote C›G, intron  
amplicone 17a: Pos . 38562732 G›T, amino acid pos. 974, K>D 
amplicone 17b: Pos. 38562471 homozygote A›G, amino acid pos. 1061, 
E›E, polimorphism rs7430407 
amplicone 24: Pos  38547178 heterozygote A›G, intron, polymorphism 
rs41312393 
amplicone 27: Pos . 38536074 deletion T, intron 
                      Pos . 38536077 homozygote T›A, intron 
amplicone 28c: Pos. 38592406 T›C, exon, amino acid pos. 1818, D>D, 
rs1805126 
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs 7429945 
amplicone 28g: Pos . 38531355 G›A, exon, mRNA position 6703, near 
3’UTR, non-translated region 
amplicone 28i : Pos . 38530853 deletion C, exon, mRNA pos. 7205, near 
3’UTR, non-translated region 
                       Pos. 38530856 insertion A,  exon, mRNA pos. 7202, near 
3’UTR, non-translated region 
                       Pos. 38530974 C›T, exon, mRNA pos. 7084, near 3’UTR, 
non-translated region 
                       Pos. 38531102 C›T, exon, mRNA pos. 6956, near 3’UTR, 
non-translated region 
amplicone 28k: Pos. 38530279 T›C, exon, mRNA pos . 7779, 3’UTR, non -
translated region, polimorphism rs41315485 
Patient 6 
Unexplained syncopes 
Posi tive pharmacological 
provocation test 
Diagnosed BS 
amplicone 4: Pos . 38603806, insertion A, intron 
                      Pos . 38603801 homozygote T›A, intron  
amplicone 6: Pos. 38595390 C›G, intron 
                      Pos. 38595384 homozygote C›G, intron 
amplicone 7: Pos . 38591480 C›G, intron 
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs 7429945 
amplicone 28i : Pos . 38530853 deletion C, exon, mRNA pos. 7205, near 
3’UTR, non-translated region 
                       Pos. 38530856 insertion A,  exon, mRNA pos. 7202, near 
3’UTR, non-translated region 
                       Pos. 38530974 C›T, exon, mRNA pos. 7084, near 3’UTR, 
non-translated region 
                       Pos. 38531102 C›T, exon, mRNA pos. 6956, near 3’UTR, 
non-translated region 
amplicone 28k: Pos. 38530279 T›C, exon, mRNA pos . 7779, 3’UTR, non -
translated region, polimorphism rs41315485 
Patient 7 
Unexplained syncopes 
Posi tive pharmacological 
provocation test 
Diagnosed BS 
amplicone 2: Pos . 38614716, A›G, amino acid pos . 29, A>A, polymorphism 
rs6599230 
                      Pos . 38614815, G›C, exon, mRNA pos.182, non -translated 
region 
 amplicone 4: Pos . 38603806, insertion A, intron 
                      Pos . 38603801 homozygote T›A, intron  
amplicone 6: Pos. 38595390 C›G, intron 
                      Pos. 38595384 homozygote C›G, intron 
amplicone 17a: Pos . 38562732 G›T, amino acid pos. 974, K>D 
amplicone 24: Pos  38547178 heterozygote A/G, intron, polymorphism 
rs41312393  
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs7429945 
amplicone 28i : Pos . 38530853 deletion C, exon, mRNA pos. 7205, near 
3’UTR, non-translated region 
                       Pos. 38530856 insertion A,  exon, mRNA pos. 7202, near 
3’UTR, non-translated region 
                       Pos. 38530974 C›T, exon, mRNA pos. 7084, near 3’UTR, 
non-translated region 
                       Pos. 38531102 C›T, exon, mRNA pos. 6956, near 3’UTR, 
non-translated region 
amplicone 28k: Pos. 38530279 T›C, exon, mRNA pos . 7779, 3’UTR, non-
translated region, polimorphism rs41315485 
Patient 8 
Asymptomatic 
Posi tive pharmacological 
provocation test 
amplicone 4: Pos . 38603806, insertion A, intron 
                      Pos . 38603801 homozygote T›A, intron  
amplicone 6: Pos. 38595390 C›G, intron 
                      Pos. 38595384 homozygote C›G, intron 
amplicone 7: Pos . 38591480 C›G, intron 
amplicone 28f: Pos . 38531693 A›G, exon, mRNA position 6365, near 3’UTR, 
non-translated region, rs 7429945 
amplicone 28i : Pos . 38530853 deletion C, exon, mRNA pos. 7205, near 
3’UTR, non-translated region 
                       Pos. 38530856 insertion A,  exon, mRNA pos. 7202, near 
3’UTR, non-translated region 
                       Pos. 38530974 C›T, exon, mRNA pos. 7084, near 3’UTR, 
non-translated region 
                       Pos. 38531102 C›T, exon, mRNA pos. 6956, near 3’UTR, 
non-translated region 
amplicone 28k: Pos. 38530279 T›C, exon, mRNA pos . 7779, 3’UTR, non -
translated region, polimorphism rs41315485 
amplicone 28l : Pos . 38529996 homozygote C›G, exon, mRNA pos. 8062, 
near 3’UTR, non-translated region 





Localization Partial alignment (WT›MT) 
1 Pos. 38631119 G›A Exon, non-translated region 
 
 









4 Pos. 38604075 G›T intron 
 









7 Pos. 38591480 C›G intron 
 
8 Pos. 38589643 insertion A intron 
 
12 Pos. 38585647 A›T intron 
 
22 Pos. 38544050 C›T intron 
 










28f Pos. 38531693 A›G 
exon, near 3’UTR, non-
translated region 
 
28g Pos. 38531355 G›A 




















28k Pos. 38530279 T›C 
3’ UTR, non-translated 
region 
 
28l Pos. 38529996 C›G 
exon, near 3’UTR, non-
translated region 
 
Table 3. The list of intronic alterations and exchanges in non-coding regions along with short 1 





Figure 1a. 12-lead ECG from a patient with positive test result (before and after test). The 4 






Figure 1b. 12-lead ECG from a patient with negative test result (before and after test).  11 
 1 
 2 
Figure2. MSSCP separation of exon 2 and exon 7 PCR products. Note that sample no. 5 and 3 
7 at exon 2 and sample no. 1 at exon 7 have distinct electrophoretic profiles suggesting the 4 
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Exon 2 Exon 7 
 1 
Figure 3.Sequence alignment of SCN5 exon 2 reference (WT) and MT amplicone detected in 2 
sample 5 (pos. 38614716 heterozygote A›G, exon, amino acid pos. 29, polymorphism 3 
rs6599230; pos. 38614815 heterozygote G›C, exon, pos. 182 in mRNA, non-translating 4 
region). White color shows changed nucleotides.  5 
  6 
1 2015 aa number  
SCN5A protein  
Detected aa 
alterations (WT/MT)  
321 
S/Y 









Figure 4. Schematic illustration of Nav1.5, showing the location of the novel putative amino 1 
acid changes. 2 
 3 




















Figure 5.A. Prediction of transmembrane, extracellular in cytoplasmic regions in SCN5a 20 
protein. Location of the three new variants is depicted as orange dots. B. Prediction of 21 
functional effects of non-synonymous mutations done in Poly-Phen2 software. All three 22 
variants have two scores from HumDiv (genomic oriented) and HumVar (diagnostic 23 
oriented). C. Prediction of intrinsically disordered regions in SCN5a (1-1400AA) done by 24 
DISOPRED3. Domain organisation shown with respect to disorederd regions. Orange color 25 
marks putative binding sites. High confidencescoreindicatedbetterchance of unstructured 26 
fragment. 27 
